---
title: "Hunan Er-kang Pharmaceutical Co.,Ltd. (300267.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300267.SZ.md"
symbol: "300267.SZ"
name: "Hunan Er-kang Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T20:19:49.131Z"
locales:
  - [en](https://longbridge.com/en/quote/300267.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300267.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300267.SZ.md)
---

# Hunan Er-kang Pharmaceutical Co.,Ltd. (300267.SZ)

## Company Overview

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate products.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hnerkang.com](https://www.hnerkang.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.65)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 185 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -12.96% |  |
| Net Profit YoY | -13.40% |  |
| P/B Ratio | 2.27 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9132929474.02 |  |
| Revenue | 1061485292.39 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -9.30% | D |
| Profit Margin | -37.26% | E |
| Gross Margin | 28.43% | C |
| Revenue YoY | -12.96% | E |
| Net Profit YoY | -13.40% | D |
| Total Assets YoY | -3.22% | D |
| Net Assets YoY | -10.32% | D |
| Cash Flow Margin | -63.80% | E |
| OCF YoY | -12.96% | E |
| Turnover | 0.21 | D |
| Gearing Ratio | 20.17% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hunan Er-kang Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-12.96%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.40%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.27",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9132929474.02",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1061485292.39",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-9.30%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-37.26%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "28.43%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-12.96%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.40%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.22%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-10.32%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-63.80%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-12.96%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.21",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "20.17%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -23.40 | 192/215 | - | - | - |
| PB | 2.30 | 104/215 | 1.88 | 1.74 | 1.58 |
| PS (TTM) | 8.72 | 172/215 | 6.74 | 6.12 | 5.68 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300267.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300267.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300267.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300267.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**